Lonza Will Boost Conjugate Capability | Chemical & Engineering News
Volume 91 Issue 2 | p. 20 | Concentrates
Issue Date: January 14, 2013

Lonza Will Boost Conjugate Capability

Department: Business
Keywords: antibody, drug, conjugates, Switzerland

The Swiss pharmaceutical chemicals firm Lonza plans to invest $15 million to expand antibody-drug conjugate (ADC) production capacity in Visp, Switzerland. Lonza calls itself a pioneer in the manufacturing of ADCs, which are now being tested against cancer in dozens of clinical trials. The firm says the project will double large-scale ADC capacity at the site when it is completed in the second quarter of 2014.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment